Gain Therapeutics Stock (NASDAQ:GANX)

Forecast Ownership Financials Chart

Previous Close

$1.80

52W Range

$0.89 - $3.65

50D Avg

$2.10

200D Avg

$1.81

Market Cap

$48.35M

Avg Vol (3M)

$250.25K

Beta

0.19

Div Yield

GANX Company Profile

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Mar 19, 2021

Website

GANX Performance

GANX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	$55.18K	$140.11K
Operating Income	$-20.35M	$-22.25M	$-17.78M
Net Income	$-20.41M	$-22.27M	$-17.59M
EBITDA	$-20.35M	$-22.17M	$-17.78M
Basic EPS	$-0.89	$-1.71	$-1.48
Diluted EPS	$-0.89	$-1.71	$-1.48

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
CSBR	Champions Oncology, Inc.
CUE	Cue Biopharma, Inc.
MOLN	Molecular Partners AG
ELVN	Enliven Therapeutics, Inc.
MNOV	MediciNova, Inc.
ANEB	Anebulo Pharmaceuticals, Inc.
INAB	IN8bio, Inc.
CELC	Celcuity Inc.
NAMS	NewAmsterdam Pharma Company N.V.
INBX	Inhibrx Biosciences, Inc.
BIVI	BioVie Inc.
LTRN	Lantern Pharma Inc.